Romain Neugebauer to HIV Infections
This is a "connection" page, showing publications Romain Neugebauer has written about HIV Infections.
Connection Strength
0.973
-
Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 06 01; 72(11):1900-1909.
Score: 0.491
-
Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clin Infect Dis. 2020 03 03; 70(6):1176-1185.
Score: 0.113
-
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
Score: 0.094
-
Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS. 2007 Jul 31; 21(12):1547-54.
Score: 0.094
-
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):413-9.
Score: 0.086
-
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
Score: 0.063
-
The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf. 2012 Jan; 21(1):49-52.
Score: 0.031